Journal of Clinical Oncology, Vol 20, Issue 7
(April), 2002: 1845-1852
© 2002 American Society for Clinical Oncology
Excellent Disease Control and Survival in Patients With Advanced Nasopharyngeal Cancer Treated With Chemoradiation
By Danny Rischin,
June Corry,
Jennifer Smith,
Josephine Stewart,
Peter Hughes,
Lester Peters
From the Division of Hematology and Medical Oncology, Division of Radiation Oncology, and Statistical Center, Peter MacCallum Cancer Institute, Melbourne, Australia.
Address reprint requests to Danny Rischin, MD, Division of Hematology and Medical Oncology, Peter MacCallum Cancer Institute, Locked Bag No 1, A’Beckett St, Melbourne 8006, Australia; email: drischin{at}petermac.unimelb.edu.au
PURPOSE: To determine the efficacy and safety of epirubicin, cisplatin, and infusional fluorouracil (5-FU) chemotherapy followed by radiation with concurrent cisplatin in patients with locally and/or regionally advanced nasopharyngeal cancer.
PATIENTS AND METHODS: Thirty-five patients were treated with three cycles of induction chemotherapy with epirubicin 50 mg/m2 and cisplatin 75 mg/m2 combined with continuous-infusion 5-FU 200 mg/m2 daily for 9 weeks, followed by concurrent chemoradiation of 60 Gy in 2-Gy fractions with cisplatin 20 mg/m2 daily for 5 days in weeks 1 and 6.
RESULTS: Median age was 43 years, 74% had World Health Organization type III histology, and 91% had stage IV disease (International Union Against Cancer, ed 4). All patients received three cycles of induction chemotherapy, and 97% completed chemoradiation. The estimated 4-year progression-free survival rate was 81% (95% CI, 59% to 93%), and the estimated 4-year overall survival rate was 90% (95% CI, 74% to 97%). Only two patients have had a locoregional relapse by the close-out date despite the use of only 60 Gy. Induction chemotherapy was well tolerated, with 11% grade 3 or 4 stomatitis, 26% grade 3 vomiting, and no episodes of febrile neutropenia. Acute toxicities of chemoradiation were as follows: 23% grade 3 or 4 vomiting, 6% febrile neutropenia, 31% grade 3 mucositis, and 23% grade 3 skin toxicity. The most prevalent grade 3 late effects were xerostomia and hearing loss.
CONCLUSION: This regimen was well tolerated, can be delivered as planned, and has resulted in excellent locoregional disease control and survival in patients with locally advanced nasopharyngeal cancer.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
E. P. Hui, B. B. Ma, S. F. Leung, A. D. King, F. Mo, M. K. Kam, B. K. Yu, S. K. Chiu, W. H. Kwan, R. Ho, et al.
Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal Carcinoma
J. Clin. Oncol.,
January 10, 2009;
27(2):
242 - 249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Maloney and M. A. Weinberg
A Comprehensive Analysis of Babe Ruth's Head and Neck Cancer
J Am Dent Assoc,
July 1, 2008;
139(7):
926 - 932.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Bentzen and A. Trotti
Evaluation of Early and Late Toxicities in Chemoradiation Trials
J. Clin. Oncol.,
September 10, 2007;
25(26):
4096 - 4103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T. C. Chan, S. F. Leung, R. K. C. Ngan, P. M. L. Teo, W. H. Lau, W. H. Kwan, E. P. Hui, H. Y. Yiu, W. Yeo, F. Y. Cheung, et al.
Overall Survival After Concurrent Cisplatin-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma
J Natl Cancer Inst,
April 6, 2005;
97(7):
536 - 539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T.T. Chua, J. Ma, J. S.T. Sham, H.-Q. Mai, D. T.K. Choy, M.-H. Hong, T.-X. Lu, and H.-Q. Min
Long-Term Survival After Cisplatin-Based Induction Chemotherapy and Radiotherapy for Nasopharyngeal Carcinoma: A Pooled Data Analysis of Two Phase III Trials
J. Clin. Oncol.,
February 20, 2005;
23(6):
1118 - 1124.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kawashima, N. Fuwa, M. Myojin, K. Nakamura, T. Toita, S. Saijo, N. Hayashi, H. Ohnishi, N. Shikama, M. Kano, et al.
A Multi-institutional Survey of the Effectiveness of Chemotherapy Combined with Radiotherapy for Patients with Nasopharyngeal Carcinoma
Jpn. J. Clin. Oncol.,
October 1, 2004;
34(10):
569 - 583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T.C. Chan, B. B.Y. Ma, Y.M. D. Lo, S.F. Leung, W.H. Kwan, E. P. Hui, T. S.K. Mok, M. Kam, L. S. Chan, S. K.W. Chiu, et al.
Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring With Plasma Epstein-Barr Virus DNA
J. Clin. Oncol.,
August 1, 2004;
22(15):
3053 - 3060.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Licitra and J. B. Vermorken
Is there still a role for neoadjuvant chemotherapy in head and neck cancer?
Ann. Onc.,
January 1, 2004;
15(1):
7 - 11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Isobe, H. Kawakami, T. Uno, S. Yasuda, T. Aruga, N. Ueno, T. Kawata, and H. Ito
Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: is Intergroup Study 0099 Feasible in Japanese Patients?
Jpn. J. Clin. Oncol.,
October 1, 2003;
33(10):
497 - 500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Licitra
Chemoradiation therapy in locally advanced nasopharyngeal cancer: which kind of cooperation?
Ann. Onc.,
April 1, 2003;
14(4):
508 - 509.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Hicks and M. P. Mac Manus
18F-FDG PET in Candidates for Radiation Therapy: Is It Important and How Do We Validate Its Impact?
J. Nucl. Med.,
January 1, 2003;
44(1):
30 - 32.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Rischin and L. J. Peters
The Local-Regionally Advanced Nasopharyngeal Carcinoma Jigsaw Puzzle: Where Does the Chemotherapy Piece Fit?
J. Clin. Oncol.,
April 15, 2002;
20(8):
1968 - 1970.
[Full Text]
[PDF]
|
|
|
|
